Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REPLIGEN CORPRGEN · Entity 486 | Director · Chief Executive Officer | October 05, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REPLIGEN CORP
Report date October 05, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,788 |
Ending reported balance
After 2026-10-05 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-10-05 · Sale · Disposed 1,333 · Balance 45,788 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Row 2 · 2026-10-05 · Exercise / conversion · Acquired 4,202 · Balance 49,990 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Row 3 · 2026-10-05 · Sale · Disposed 4,202 · Balance 45,788 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $154.96 · Expires 2033-10-02 | Direct | 8,405 |
Reported balance
After 2026-10-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-05 · Exercise / conversion · Disposed 4,202 · Balance 8,405 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. F2: 4,202 shares will vest on October 2, 2027. 4,203 shares will vest on October 2, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.
F2: 4,202 shares will vest on October 2, 2027. 4,203 shares will vest on October 2, 2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 6, 2026 20:18 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,202 | $0.00 Strike: $154.96 | $0.00 |
DisclosureSEC source: 0001628280-26-065238 · wk-form4_1791317904.xml · derivative · entry 4 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,405 Underlying: Common Stock · 4,202 shares Expires 2033-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. F2 · derivative.exercise_date: 4,202 shares will vest on October 2, 2027. 4,203 shares will vest on October 2, 2028. Read SEC document |
| October 05, 2026 Filed Oct 6, 2026 20:18 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 4,202 | $190.00 | $798,380.00 |
DisclosureSEC source: 0001628280-26-065238 · wk-form4_1791317904.xml · nonDerivative · entry 3 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,788 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| October 05, 2026 Filed Oct 6, 2026 20:18 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 4,202 | $154.96 | $651,141.92 |
DisclosureSEC source: 0001628280-26-065238 · wk-form4_1791317904.xml · nonDerivative · entry 2 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| October 05, 2026 Filed Oct 6, 2026 20:18 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,333 | $178.75 | $238,273.75 |
DisclosureSEC source: 0001628280-26-065238 · wk-form4_1791317904.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,788 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| October 02, 2026 Filed Oct 5, 2026 20:01 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 1,248 | $181.70 | $226,761.60 |
DisclosureSEC source: 0001628280-26-064889 · wk-form4_1791230479.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,121 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:09 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,542 | $0.00 Strike: $155.38 | $0.00 |
DisclosureSEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · derivative · entry 6 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,085 Underlying: Common Stock · 4,542 shares Expires 2035-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. F3 · derivative.exercise_date: 4,542 shares will vest on March 1, 2027, and 4,543 shares will vest on March 1, 2028. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:09 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,404 | $0.00 Strike: $154.96 | $0.00 |
DisclosureSEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · derivative · entry 5 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,607 Underlying: Common Stock · 8,404 shares Expires 2033-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. F2 · derivative.exercise_date: 4,202 shares will vest on each of October 2, 2026, and October 2, 2027. 4,203 shares will vest on October 2, 2028. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:09 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 4,542 | $190.00 | $862,980.00 |
DisclosureSEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · nonDerivative · entry 4 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,369 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:09 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 4,542 | $155.38 | $705,735.96 |
DisclosureSEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · nonDerivative · entry 3 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:09 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 8,404 | $190.00 | $1,596,760.00 |
DisclosureSEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · nonDerivative · entry 2 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,369 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:09 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 8,404 | $154.96 | $1,302,283.84 |
DisclosureSEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| September 21, 2026 Filed Sep 22, 2026 20:07 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,426 | $0.00 Strike: $141.79 | $0.00 |
DisclosureSEC source: 0001628280-26-063026 · wk-form4_1790107640.xml · derivative · entry 3 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,426 Underlying: Common Stock · 5,426 shares Expires 2034-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| September 21, 2026 Filed Sep 22, 2026 20:07 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 5,426 | $180.00 | $976,680.00 |
DisclosureSEC source: 0001628280-26-063026 · wk-form4_1790107640.xml · nonDerivative · entry 2 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,369 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| September 21, 2026 Filed Sep 22, 2026 20:07 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 5,426 | $141.79 | $769,352.54 |
DisclosureSEC source: 0001628280-26-063026 · wk-form4_1790107640.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| September 04, 2026 Filed Sep 8, 2026 20:13 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 3,035 | $165.90 | $503,506.50 |
DisclosureSEC source: 0001628280-26-060911 · wk-form4_1788898417.xml · nonDerivative · entry 2 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,369 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 20:13 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 2,842 | $169.61 | $482,031.62 |
DisclosureSEC source: 0001628280-26-060911 · wk-form4_1788898417.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,404 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy the tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 20:06 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,426 | $0.00 Strike: $141.79 | $0.00 |
DisclosureSEC source: 0001628280-26-058417 · wk-form4_1787342788.xml · derivative · entry 3 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,852 Underlying: Common Stock · 5,426 shares Expires 2034-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. F2 · derivative.exercise_date: 5,426 shares will vest on each of September 3, 2026, and September 3, 2027. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 20:06 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 5,426 | $180.00 | $976,680.00 |
DisclosureSEC source: 0001628280-26-058417 · wk-form4_1787342788.xml · nonDerivative · entry 2 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,246 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 20:06 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 5,426 | $141.79 | $769,352.54 |
DisclosureSEC source: 0001628280-26-058417 · wk-form4_1787342788.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| April 21, 2026 Filed Apr 22, 2026 17:26 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 3,832 | $140.00 | $536,480.00 |
DisclosureSEC source: 0001193125-26-169682 · ownership.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,246 F1 · price: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on August 19th, 2025. Read SEC document |
| March 05, 2026 Filed Mar 23, 2026 15:53 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 25,890 | $0.00 Strike: $141.91 | $0.00 |
DisclosureSEC source: 0001193125-26-119036 · ownership.xml · derivative · entry 2 Loeillot Olivier · CIK 0001995525 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,890 Underlying: Common Stock · 25,890 shares Expires 2036-03-05 F2 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029. Read SEC document |
| March 05, 2026 Filed Mar 23, 2026 15:53 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 24,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-119036 · ownership.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,078 F1 · shares: Mr. Loeillot was awarded 24,134 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 18:39 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 1,610 | $124.97 | $201,201.70 |
DisclosureSEC source: 0001193125-26-087595 · ownership.xml · nonDerivative · entry 2 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,944 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 18:39 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 344 | $128.73 | $44,283.12 |
DisclosureSEC source: 0001193125-26-087595 · ownership.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,554 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 21:30 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 7,041 | $170.00 | $1,196,970.00 |
DisclosureSEC source: 0001193125-25-300642 · ownership.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,898 F1 · price: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 12, 2024. Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 14:59 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 1,248 | $145.23 | $181,247.04 |
DisclosureSEC source: 0001193125-25-231365 · ownership.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,939 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 14:55 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 2,506 | $116.18 | $291,147.08 |
DisclosureSEC source: 0001193125-25-195655 · ownership.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,187 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 18:18 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 13,627 | $0.00 Strike: $155.38 | $0.00 |
DisclosureSEC source: 0000950170-25-031547 · ownership.xml · derivative · entry 2 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,627 Underlying: Common Stock · 13,627 shares Expires 2035-03-03 F2 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on March 3, 2026, March 3, 2027, and March 3, 2028. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 18:18 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 14,480 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-031547 · ownership.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,693 F1 · shares: Mr. Loeillot was awarded 14,480 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 21:30 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 343 | $156.54 | $53,693.22 |
DisclosureSEC source: 0000950170-25-030080 · ownership.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,213 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of performance stock units. Read SEC document |
| November 20, 2024 Filed Nov 21, 2024 18:32 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 861 | $123.41 | $106,256.01 |
DisclosureSEC source: 0000950170-24-129622 · ownership.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,556 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:41 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 16,278 | $0.00 Strike: $141.79 | $0.00 |
DisclosureSEC source: 0000950170-24-103643 · ownership.xml · derivative · entry 2 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,278 Underlying: Common Stock · 16,278 shares Expires 2034-09-03 F2 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on September 3, 2025, September 3, 2026, and September 3, 2027. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:41 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 17,631 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-103643 · ownership.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,417 F1 · shares: Mr. Loeillot was awarded 17,631 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| February 27, 2024 Filed Mar 1, 2024 00:07 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 2,860 | $0.00 Strike: $192.71 | $0.00 |
DisclosureSEC source: 0000950170-24-023416 · ownership.xml · derivative · entry 2 Loeillot Olivier · CIK 0001995525 · President and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,860 Underlying: Common Stock · 2,860 shares Expires 2034-02-27 F2 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on February 27, 2025, February 27, 2026 and February 27, 2027. Read SEC document |
| February 27, 2024 Filed Mar 1, 2024 00:07 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 2,880 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023416 · ownership.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · President and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,786 F1 · shares: Mr. Loeillot was awarded 2,880 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 00:44 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 24,236 | $0.00 Strike: $154.96 | $0.00 |
DisclosureSEC source: 0000950170-23-051753 · ownership.xml · derivative · entry 2 Loeillot Olivier · CIK 0001995525 · President and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,236 Underlying: Common Stock · 24,236 shares Expires 2033-10-02 F2 · derivative.exercise_date: The shares vest in equal annual installments over a five-year period with each such vesting date occurring on the anniversary of the grant date. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 00:44 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 12,906 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-051753 · ownership.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · President and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,906 F1 · shares: Mr. Loeillot was awarded 12,906 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal installments over a five-year period with each such vesting date occurring on the anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.